vimarsana.com

Brainpath Automated Preservation News Today : Breaking News, Live Updates & Top Stories | Vimarsana

MUSC s first preclinical use of BrainPath technology drives major PDX brain tumor model development

Date Time MUSC’s first preclinical use of BrainPath technology drives major PDX brain tumor model development In a field with notoriously poor outcomes, MUSC neurologists have developed a new brain cancer model to help to address challenging clinical problems. Neuroscientist Arabinda Das, Ph.D., and neurosurgeon Bruce Frankel, M.D., have developed the first clinically relevant patient-derived xenograft (PDX) brain tumor model using NICO Corp.’s BrainPath Automated Preservation System. BrainPath is a critical technology in minimally invasive parafascicular surgery, or MIPS, which allows neurosurgeons to reach deeper brain lesions safely with minimal disruption to the surrounding healthy brain tissue. Cleared by the FDA in 2012, the instrument was first used at MUSC in 2015. While BrainPath is now used in many of the top operating rooms across the country, MUSC is the first to employ this cutting-edge technology in an animal model.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.